These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26367539)

  • 21. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
    Wyce A; Degenhardt Y; Bai Y; Le B; Korenchuk S; Crouthame MC; McHugh CF; Vessella R; Creasy CL; Tummino PJ; Barbash O
    Oncotarget; 2013 Dec; 4(12):2419-29. PubMed ID: 24293458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
    McLure KG; Gesner EM; Tsujikawa L; Kharenko OA; Attwell S; Campeau E; Wasiak S; Stein A; White A; Fontano E; Suto RK; Wong NC; Wagner GS; Hansen HC; Young PR
    PLoS One; 2013; 8(12):e83190. PubMed ID: 24391744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
    Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
    Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
    Dittmann A; Werner T; Chung CW; Savitski MM; Fälth Savitski M; Grandi P; Hopf C; Lindon M; Neubauer G; Prinjha RK; Bantscheff M; Drewes G
    ACS Chem Biol; 2014 Feb; 9(2):495-502. PubMed ID: 24533473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
    Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM
    Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of linker length effects on a BET bromodomain probe.
    Traquete R; Henderson E; Picaud S; Cal PMSD; Sieglitz F; Rodrigues T; Oliveira R; Filippakopoulos P; Bernardes GJL
    Chem Commun (Camb); 2019 Aug; 55(68):10128-10131. PubMed ID: 31386708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disrupting the reader of histone language.
    Oliver SS; Denu JM
    Angew Chem Int Ed Engl; 2011 Jun; 50(26):5801-3. PubMed ID: 21618372
    [No Abstract]   [Full Text] [Related]  

  • 35. 4-Methyl-1,2,3-Triazoles as
    Cui H; Carlson AS; Schleiff MA; Divakaran A; Johnson JA; Buchholz CR; Zahid H; Vail NR; Shi K; Aihara H; Harki DA; Miller GP; Topczewski JJ; Pomerantz WCK
    J Med Chem; 2021 Jul; 64(14):10497-10511. PubMed ID: 34236185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
    Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
    Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
    Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
    Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
    Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.